AD Pipeline Watch: Rocatinlimab, an Anti-OX40 Monoclonal Antibody, Shows Sustained Safety, Efficacy
Rocatinlimab showed sustained efficacy in improving skin clearance and itch in moderate-to-severe atopic dermatitis (AD), with a favorable safety profile, according to topline findings from the Phase 3 ASCEND trial.